Methylprednisolone嵌段式聚合微膠體劑型在家兔之藥物動力學研究

Pharmacokinetic studies of Methylprednisolone in Rabbits by Polymeric Micelle Formulation

李克繼(Daniel Lei)

指導教授 ： 廖嘉鴻

臺北醫學大學/藥學院/藥學研究所/碩士(2005年)

摘要

利用兩種嵌段式共聚合物微膠體(polymeric micelles, PM):PM1, PM2為載體以物理性包覆(physical entrapment)方式製備，改善水難溶性皮質類固醇藥物methylprednisolone(MP)的溶解度，延長MP於血中的半衰期，並增加MP於脊髓的蓄積，為本次實驗的目的。 在嵌段式共聚合物的物理化學性質方面，分別測試臨界膠質體濃度並評估嵌段式共聚合物的MP的溶解度及其粒徑大小與釋放速率。並利用紐西蘭白兔之十二指腸，以體外實驗方式研究藥物與PM1及PM2穿透的情形。動物實驗方面，以雄性紐西蘭白兔為實驗動物，以兩種給藥途徑分別是靜脈注射與口服給藥，給與單一劑量的MP，分別溶於水或嵌段式共聚合物水溶液中，於不同時間點採血與脊髓分析其濃度。 由實驗結果顯示， PM1、 PM2臨界膠質體濃度分別是0.1% (w/w)、0.01%(w/w)，溶解度從60?g/ml(MP/H2O)增加到220?g/ml(MP/PM1)及110?g/ml(MP/PM2)，粒徑大小分別是60nm(PM1)及10nm(PM2)，嵌段式共聚合物的MP的藥物釋放速率在MP/PM1劑型有緩釋的效果。而MP的穿透會受到P-glycoprotein影響，分別加入PM1或PM2後，可增加MP穿透量。本次實驗動物檢品使用高效液相層析儀(HPLC)分析，建立兩種分析條件，分析血漿檢品與脊髓檢品。動物之血漿檢品與脊髓檢品在經高效液相層析儀分析後之結果，嵌段式共聚合物的MP有半衰期延長與增加脊髓的藥物蓄積的結果。藥物動力學參數方面，分別以靜脈注射MP/H2O，MP/PM1， MP/PM2後，排除半衰期分別為76.1±8.0 min，514.3±70.0 min，428.5±100.2 min、清除率(Cl) 分別為26.3±3.0，8.8±1.5，12.6±1.2 mL/min、AUC分別為42.6±7.9， 140.0±34.3，83.3±8.1 min??g/mL。而分別口服MP/H2O，MP/PM1， MP/PM2後，半衰期分別為79.0±1.7 min，416.4±55.9 min，428.0±39.9 min、清除率分別為24.3±2.1，8.1±1.1，12.8±1.4 mL/min、AUC分別為 19.2±1.6，75.5±13.5，82.3±11.3 min??g/mL。在統計上以ANOVA分析之結果均有差異。以口服投藥後，嵌段式共聚合物包覆MP對靜脈注射MP/H2O之身體可用率分別是0.8 (MP/PM1)及1.2 (MP/PM2)。

關鍵字

嵌段式聚合微膠體劑型

並列摘要

The purpose of thesis study was used two polymeric micelles (PM1, PM2) formulation for methylprednisolone (MP) to developed (1) prolong circulation of MP in blood and (2) enhancement of accumulation of MP in spinal cord. In physicochemical properties of two formulations (MP/PM1, MP/PM2): solubility, CMC, particle size and release rate was tested. In addition, in vitro permeations of MP/PM1 and MP/PM2 were evaluated on duodenal of rabbit. Male New Zealand rabbits received oral and a IV bolus dose of MP (MP/PM1, MP/PM2, MP/H2O). The critical micelle concentration of two formulation of PM1 and PM2 values were 0.1% and 0.01%, respectively. The solubility of MP was also observed increasing from 60?g/ml (MP/H20) to 220?g/ml (MP/PM1) and 100?g/ml (MP/PM2). Particle size was found 60nm and 10nm for PM1, PM2, respectively. MP/PM1 show slow release rate by cellulose membrane tested. After incubation of P-gp inhibitor and concentration-dependence, we found that PM1, and PM2 could modify the MP transport of duodenum from Apical to Basical direction. After IV administration of three formulation (MP/H20, MP/PM1, MP/PM2): terminal half-life (t1/2β)was increased from 76 to 514 and 428 min; clearance, from 26 to 9 and 13 mL/min; AUC0→∞, from 42 to 140 and 83.3 min??g/mL, respectively. After oral delivery of three formulation the terminal half-life (t1/2β) was increased from 79 (MP/H20) to 416 (MP/PM1) and 428 min(MP/PM2); clearance was decreased from 24 to 8 and 13 mL/min; AUC0→∞ was increased from 19 to 75 and 82 min??g/mL, respectively. After oral administration of MP/PM1 and MP/PM2 the absolute bioavailability was found 0.8 and 1.2, respectively. Finally, we could observed that PM1, PM2 could prolong the blood circulation time and enhancement of MP in spinal cord.

並列關鍵字

Methylprednisolone (MP)

參考文獻

1. D. Czock, F. Keller, F.M. Rasche and U. Haussler. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clinical Pharmacokinetics. 2005; 44(1):61-98.

2. B. K. Kwon, W. Tezlaff, J. N. Grauer, , J. Beiner, A. R. Vaccaro. Pathophysiology and pharmacologic treatment of acute spinal cord injury. The Spinal Jounal. 2004; 4:451-464.

4. M. B. Bracken, M. J. Shepard , W. F. Collins , T. R. Holford , W. Young , D. S. Baskin , H. M. Eisenberg , E. Flamm , L . Leo-Summers , J. Maroon. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. New England Journal of Medicine.1990; 322(20):1405-11.

5. F. H. Geisler , F. C. Dorsey , W. P. Coleman. Recovery of motor function after spinal-cord injury--a randomized, placebo-controlled trial with GM-1 ganglioside. New England Journal of Medicine. 1991; 324(26):1829-38.

6. M. B. Bracken , M. J. Shepard , T. R. Holford , L . Leo-Summers , E. F. Aldrich , M . Fazl , M . Fehlings, D. L. Herr , P. W. Hitchon , L. F. Marshall , R.P. Nockels , V. Pascale , P. L. Perot , J. Piepmeier , V. K. Sonntag , F. Wagner, J. E. Wilberger , H.R. Winn , W. Young . Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third national acute spinal cord injury randomized controlled trial. national acute spinal cord injury study. Journal of the American Medical Association. 1997; 277(20):1597-604.